A new study has mapped the effects of ketamine on the brain, finding that repeated use over extended periods creates...
Mindset Pharma says its next-generation psilocybin compounds could change the paradigm of microdosing by limiting the psychedelic effect.
Tryp Therapeutics has completed psychotherapy training for its upcoming Phase 2a psilocybin clinical trial.
Braxia Scientific will be carrying out a landmark clinical trial investigating multiple-dose psilocybin for treatment-resistant depression.
A psychedelic medicine startup will be developing a transdermal patch for sustained delivery of psilocin.
Cybin has filed two international patent applications to support its psychedelic research phases programmes.
People will now be able to participate in psychedelic-assisted therapy in a group setting as the Institute for Integrative Therapies expands its services to support the...
Awakn Life Sciences will be carrying out the first-ever study investigating the use of ketamine treatment for gambling addiction, using psychedelic-assisted psychotherapy.
Mydecine Innovations Group has signed a five-year psychedelic research agreement with Johns Hopkins University School of Medicine.
Psycheceutical has been granted exclusive license of two major patents that will psychedelic compounds to be administered without any side effects.
Diamond Therapeutics has received approval from Health Canada to carry out a clinical trial for the treatment of mental health conditions with low-dose psilocybin.
The Psychedelic Coalition for Health has launched to educate healthcare professionals in psychedelic-assisted therapy and integration in a bid to meet the growing need for trained...